121 related articles for article (PubMed ID: 16609062)
1. Molecular targets in melanoma from angiogenesis to apoptosis.
Sosman JA; Puzanov I
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
[TBL] [Abstract][Full Text] [Related]
2. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Panka DJ; Atkins MB; Mier JW
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
[TBL] [Abstract][Full Text] [Related]
3. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
4. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and targeted therapy combinations in advanced melanoma.
Flaherty KT
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
[TBL] [Abstract][Full Text] [Related]
6. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for uveal melanoma.
Triozzi PL; Eng C; Singh AD
Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
[TBL] [Abstract][Full Text] [Related]
8. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
10. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells.
Marín YE; Wall BA; Wang S; Namkoong J; Martino JJ; Suh J; Lee HJ; Rabson AB; Yang CS; Chen S; Ryu JH
Melanoma Res; 2007 Oct; 17(5):274-83. PubMed ID: 17885582
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted therapy for melanoma: current reality and future options.
Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.
Basu B; Biswas S; Wrigley J; Sirohi B; Corrie P
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1583-98. PubMed ID: 19895243
[TBL] [Abstract][Full Text] [Related]
13. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
14. Prospects for non-immunological molecular therapeutics in melanoma.
Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
[TBL] [Abstract][Full Text] [Related]
15. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
16. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
17. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.
Hersey P; Zhuang L; Zhang XD
Int Rev Cytol; 2006; 251():131-58. PubMed ID: 16939779
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
Lorigan P; Eisen T; Hauschild A
Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
[TBL] [Abstract][Full Text] [Related]
19. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
20. Melanoma treatment update.
Tsao H; Sober AJ
Dermatol Clin; 2005 Apr; 23(2):323-33. PubMed ID: 15837158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
